{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cetuximab&page=7", "query": { "intervention": "cetuximab", "page": 7 }, "page_size": 10 }, "pagination": { "page": 7, "page_size": 10, "total_count": 559, "total_pages": 56, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cetuximab&page=8&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cetuximab&page=6&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-25T10:57:13.585Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01294826", "title": "Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Colon Cancer", "Recurrent Rectal Cancer", "Stage IV Colon Cancer", "Stage IV Rectal Cancer", "Adenocarcinoma of the Colon", "Adenocarcinoma of the Rectum" ], "interventions": [ { "name": "AUY922", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Swedish Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2011-02", "completion_date": "2015-05", "has_results": false, "last_update_posted_date": "2015-06-08", "last_synced_at": "2026-10-25T10:57:13.585Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01294826" }, { "nct_id": "NCT00968435", "title": "Bevacizumab, Cetuximab, and Cisplatin With IMRT (Intensity-Modulated Radiation Therapy) for Patients With Stage III/IV Head and Neck Squamous Cell Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "bevacizumab, cisplatin, cetuximab, radiation therapy", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2009-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2016-08-10", "last_synced_at": "2026-10-25T10:57:13.585Z", "location_count": 5, "location_summary": "Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Rockville Centre", "state": "New York" }, { "city": "Sleepy Hollow", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00968435" }, { "nct_id": "NCT06024174", "title": "A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "BMS-986466", "type": "DRUG" }, { "name": "Adagrasib", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2023-11-09", "completion_date": "2024-05-13", "has_results": true, "last_update_posted_date": "2025-07-22", "last_synced_at": "2026-10-25T10:57:13.585Z", "location_count": 4, "location_summary": "Los Angeles, California • Athens, Georgia • Hackensack, New Jersey + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Athens", "state": "Georgia" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Morristown", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT06024174" }, { "nct_id": "NCT01931150", "title": "Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cetuximab-induced Papulopustular (Acneiform) Rash Who Have", "Metastatic Colorectal Cancer or Head and Neck Squamous Cell Carcinoma" ], "interventions": [ { "name": "Topical Dapsone 5% Gel", "type": "DRUG" }, { "name": "Moisturizer", "type": "OTHER" }, { "name": "oral antibiotics", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2013-08", "completion_date": "2015-09", "has_results": true, "last_update_posted_date": "2017-01-13", "last_synced_at": "2026-10-25T10:57:13.585Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01931150" }, { "nct_id": "NCT02741570", "title": "Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Cetuximab/Erbitux", "type": "DRUG" }, { "name": "Cisplatin/Platinol", "type": "DRUG" }, { "name": "Carboplatin/Paraplatin", "type": "DRUG" }, { "name": "Fluorouracil/Adrucil", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 947, "start_date": "2016-10-05", "completion_date": "2022-09-22", "has_results": true, "last_update_posted_date": "2023-09-21", "last_synced_at": "2026-10-25T10:57:13.585Z", "location_count": 22, "location_summary": "Tucson, Arizona • Duarte, California • Stanford, California + 16 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02741570" }, { "nct_id": "NCT03563170", "title": "QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hepatocellular Carcinoma Non-resectable", "Hepatocellular Carcinoma Recurrent" ], "interventions": [ { "name": "ETBX-011", "type": "BIOLOGICAL" }, { "name": "GI-4000", "type": "BIOLOGICAL" }, { "name": "haNK for infusion", "type": "BIOLOGICAL" }, { "name": "avelumab", "type": "BIOLOGICAL" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "nab-Paclitaxel", "type": "DRUG" }, { "name": "Sorafenib", "type": "DRUG" }, { "name": "SBRT", "type": "PROCEDURE" }, { "name": "Aldoxorubicin hydrochloride", "type": "BIOLOGICAL" }, { "name": "ETBX-051", "type": "BIOLOGICAL" }, { "name": "ETBX-061", "type": "BIOLOGICAL" }, { "name": "GI-6207", "type": "BIOLOGICAL" }, { "name": "GI-6301", "type": "BIOLOGICAL" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "N-803", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "ImmunityBio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2018-05-25", "completion_date": "2019-08-23", "has_results": false, "last_update_posted_date": "2021-03-18", "last_synced_at": "2026-10-25T10:57:13.585Z", "location_count": 1, "location_summary": "El Segundo, California", "locations": [ { "city": "El Segundo", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03563170" }, { "nct_id": "NCT01326923", "title": "Induction Chemo Then Concurrent Chemoradiotherapy With Cetuximab in Locally Advanced Head and Neck Squamous Cell Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Squamous Cell Cancer" ], "interventions": [ { "name": "Cetuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Louisiana State University Health Sciences Center Shreveport", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2010-06", "completion_date": "2014-02", "has_results": true, "last_update_posted_date": "2020-10-09", "last_synced_at": "2026-10-25T10:57:13.585Z", "location_count": 1, "location_summary": "Shreveport, Louisiana", "locations": [ { "city": "Shreveport", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT01326923" }, { "nct_id": "NCT02855086", "title": "Cetuximab-IRDye 800CW in Detecting Tumors in Patients With Malignant Glioma Undergoing Surgery", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Brain Neoplasm", "Malignant Glioma" ], "interventions": [ { "name": "Cetuximab", "type": "BIOLOGICAL" }, { "name": "Cetuximab-IRDye 800CW", "type": "DRUG" }, { "name": "Tumor resection", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Eben Rosenthal", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2016-10", "completion_date": "2016-11-22", "has_results": true, "last_update_posted_date": "2020-03-31", "last_synced_at": "2026-10-25T10:57:13.585Z", "location_count": 1, "location_summary": "Palo Alto, California", "locations": [ { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02855086" }, { "nct_id": "NCT02713373", "title": "Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Recurrent Colorectal Carcinoma", "Stage IVA Colorectal Cancer", "Stage IVB Colorectal Cancer" ], "interventions": [ { "name": "Cetuximab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2016-08-05", "completion_date": "2021-07-20", "has_results": true, "last_update_posted_date": "2022-10-06", "last_synced_at": "2026-10-25T10:57:13.585Z", "location_count": 2, "location_summary": "Buffalo, New York • Cleveland, Ohio", "locations": [ { "city": "Buffalo", "state": "New York" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02713373" }, { "nct_id": "NCT06585488", "title": "A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Solid Tumors", "Advanced Non-squamous Non-small-cell Lung Cancer", "Advanced Colorectal Cancer", "Advanced Pancreatic Ductal Adenocarcinoma", "Advanced Gastric Cancer", "Advanced Gastroesophageal Junction Cancer", "Advanced Esophageal Adenocarcinoma" ], "interventions": [ { "name": "BGB-53038", "type": "DRUG" }, { "name": "Tislelizumab", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeOne Medicines", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 47, "start_date": "2024-12-13", "completion_date": "2026-04-23", "has_results": false, "last_update_posted_date": "2026-07-08", "last_synced_at": "2026-10-25T10:57:13.585Z", "location_count": 4, "location_summary": "Los Angeles, California • Kansas City, Kansas • Baltimore, Maryland + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06585488" } ] }